Timing of significant adverse events is essential information during early development of new drugs. - Suppr | 超能文献

Timing of significant adverse events is essential information during early development of new drugs.

作者信息

Hyodo Ichinosuke

出版信息

Int J Clin Oncol. 2006 Feb;11(1):69; author reply 69-70. doi: 10.1007/s10147-005-0521-x.

DOI:10.1007/s10147-005-0521-x

Abstract

摘要

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1

Timing of significant adverse events is essential information during early development of new drugs.

Int J Clin Oncol. 2006 Feb;11(1):69; author reply 69-70. doi: 10.1007/s10147-005-0521-x.

2

The use of capecitabine in cancer: management of the hand foot syndrome.

Acta Med Indones. 2005 Jul-Sep;37(3):174-6.

3

A Japanese phase I study of continuous oral capecitabine in patients with malignant solid tumors.一项关于连续口服卡培他滨治疗恶性实体瘤患者的日本I期研究。

Int J Clin Oncol. 2005 Feb;10(1):51-7. doi: 10.1007/s10147-004-0460-y.

4

[Use of xeloda (capecitabine) in the treatment of cancer patients (review)].希罗达（卡培他滨）在癌症患者治疗中的应用（综述）

Ter Arkh. 2003;75(10):65-70.

5

Capecitabine: have we got the dose right?卡培他滨：我们的剂量正确吗？

Nat Clin Pract Oncol. 2009 Jan;6(1):17-24. doi: 10.1038/ncponc1240. Epub 2008 Oct 21.

6

Dear doctor: we really are not sure what dose of capecitabine you should prescribe for your patient.尊敬的医生：我们真的不确定您应该为您的患者开多大剂量的卡培他滨。

J Clin Oncol. 2002 Mar 15;20(6):1434-5. doi: 10.1200/JCO.2002.20.6.1434.

7

Capecitabine-induced oromandibular dystonia: a case report and literature review.

Acta Oncol. 2008;47(6):1161-5. doi: 10.1080/02841860701721785.

8

A phase I study of the oral platinum agent satraplatin in sequential combination with capecitabine in the treatment of patients with advanced solid malignancies.一项评估口服铂类药物 satraplatin 与卡培他滨序贯联合治疗晚期实体瘤患者的 I 期临床研究。

Acta Oncol. 2011 Oct;50(7):1105-10. doi: 10.3109/0284186X.2010.543697. Epub 2010 Dec 27.

9

[Cardiotoxicity induced by 5-fluorouracil or capecitabine].[5-氟尿嘧啶或卡培他滨所致心脏毒性]

Ugeskr Laeger. 2010 Jan 4;172(1):48-51.

10

Cancer chemotherapy and cardiovascular risks: is capecitabine-induced hypertriglyceridemia a rare adverse effect?癌症化疗与心血管风险：卡培他滨诱导的高甘油三酯血症是一种罕见的不良反应吗？

Cardiology. 2010;116(1):42-4. doi: 10.1159/000313517. Epub 2010 Apr 29.

本文引用的文献

1

A Japanese phase I study of continuous oral capecitabine in patients with malignant solid tumors.一项关于连续口服卡培他滨治疗恶性实体瘤患者的日本I期研究。

Int J Clin Oncol. 2005 Feb;10(1):51-7. doi: 10.1007/s10147-004-0460-y.

2

Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine.新型口服氟嘧啶氨基甲酸酯——卡培他滨的初步研究。

J Clin Oncol. 1998 May;16(5):1795-802. doi: 10.1200/JCO.1998.16.5.1795.